Aastrom Biosciences is the leading developer of patient-specific, expanded multicellular therapies for treating severe, chronic cardiovascular diseases. The company’s proprietary cell-processing technology enables the manufacturing of ixmyelocel-T, which is a patent-specific multicellular therapy expanded from a patient’s own bone marrow and then directly delivered to damaged tissues. The company has taken this therapy into late-stage clinical development, including a Phase 3 clinical program and a Phase 2b clinical trial. For more information, visit the company’s Web site at www.aastrom.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: